NEW

Exactech Appoints New Chief Financial Officer

Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, has announced Kerem Bolukbasi as its new chief financial officer (CFO). Bolukbasi joins Exactech from TPG Capital where he...

Philips launches Rapid Equipment Deployment Kit to COVID-19 response

Royal Philips has introduced its Rapid Equipment Deployment Kit for ICU ramp-ups, allowing doctors, nurses, technicians and hospital staff to quickly support critical care patient monitoring capabilities during the COVID-19 pandemic. Currently successfully in use in...

Pure Processing Hires New CFO

Pure Processing LLC, developer and provider of pre-cleaning stations, technologies and accessories for health care reprocessing departments, has announced the appointment of Carrie Pasinski, an experienced finance and operations leader, as chief financial officer for...

Delay in breast cancer operations due to COVID-19 pandemic appears to be non-life-threatening for women with early-stage disease

Results of Journal of the American College of Surgeons study should reassure breast cancer patients who experienced surgical postponements due to COVID-19 pandemic A new breast cancer study brings reassuring findings for women with early-stage breast cancer who were...

TSO3 Details Results of Prion Inactivation Studies

TSO3 Inc. has announced that an independent laboratory has completed studies demonstrating the efficacy of the STERIZONE VP4 Sterilizer for inactivation of prions.

Prions are abnormal, pathogenic agents believed to cause transmissible spongiform encephalopathies (TSEs), such as Variant Creutzfeldt-Jakob Disease. TSEs are rapidly progressive, uniformly fatal neurodegenerative diseases that can infect humans and animals. Prions generated great public concern after an outbreak of bovine spongiform encephalopathy occurred in many European countries and scientific evidence indicated its transmission to humans. Prions are unique in demonstrating a high level of resistance to conventional device reprocessing methods and have been linked to patient-to-patient transmission via contaminated medical devices.

“This study reinforces the broader clinical applications of our sterilization technology,” stated TSO3 President and CEO R.M. “Ric” Rumble. “Results obtained by the independent laboratory confirmed the efficacy and performance of the STERIZONE VP4 Sterilizer for prion inactivation. This data enables the Company to pursue approval from regulators in Europe to be listed as a device that inactivates these challenging infectious agents.”

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X